On November 21, 2024, GT Biopharma, Inc. (NASDAQ: GTBP) announced in an SEC filing that it had received a notice from the Nasdaq Listing Qualifications Staff regarding non-compliance with Nasdaq Listing Rule 5550(b)(1). The letter from Nasdaq stated that the company’s stockholders’ equity had fallen below the required minimum of $2,500,000 for continued listing as […]